Verdiperstat
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Verdiperstat
- DrugBank Accession Number
- DB12440
- Background
Verdiperstat has been used in trials studying the basic science and treatment of Multiple System Atrophy (MSA).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 253.32
Monoisotopic: 253.088497909 - Chemical Formula
- C11H15N3O2S
- Synonyms
- Verdiperstat
- External IDs
- AZD3241
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrrolopyrimidines. These are compounds containing a pyrrolopyrimidine moiety, which consists of a pyrrole ring fused to a pyrimidine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyrrolopyrimidines
- Sub Class
- Not Available
- Direct Parent
- Pyrrolopyrimidines
- Alternative Parents
- Pyrimidones / Pyrimidinethiones / 2-Thiopyrimidines / Vinylogous amides / Pyrroles / Heteroaromatic compounds / Thioureas / Lactams / Dialkyl ethers / Azacyclic compounds show 3 more
- Substituents
- 2-thiopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Organic nitrogen compound / Organic oxide show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TT3345YXVR
- CAS number
- 890655-80-8
- InChI Key
- FVJCUZCRPIMVLB-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17)
- IUPAC Name
- 1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one
- SMILES
- CC(C)OCCN1C2=C(NC=C2)C(=O)NC1=S
References
- General References
- Not Available
- External Links
- PDB Entries
- 5rs7
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Multiple System Atrophy (MSA) 1 2 Completed Basic Science Parkinson's Disease (PD) 1 2 Completed Treatment Multiple System Atrophy (MSA) 1 2 Completed Treatment Parkinson's Disease (PD) 1 2, 3 Completed Treatment Amyotrophic Lateral Sclerosis (ALS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.283 mg/mL ALOGPS logP 1.26 ALOGPS logP 1.23 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 11.39 Chemaxon pKa (Strongest Basic) -4.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 57.36 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 69.73 m3·mol-1 Chemaxon Polarizability 26.44 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0006-9410000000-60e525e581bdb08dec00 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0udi-0090000000-554e3fe17a9984517c27 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-1970000000-b605f5d0c492a16f1ff7 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03xu-0970000000-3a4f29bd1615714a423b Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0fr6-0910000000-c2d38a2c9b5f255b08ff Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-7940000000-f83053fafd574e2ee9d1 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-8900000000-84586620e7391b566b06 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 149.84047 predictedDeepCCS 1.0 (2019) [M+H]+ 152.19847 predictedDeepCCS 1.0 (2019) [M+Na]+ 159.72105 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:24 / Updated at February 21, 2021 18:53